Caroline Imbert
YOU?
Author Swipe
View article: BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells
BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells Open
Butyrophilins (BTNs) are emerging as novel druggable immune targets in oncology, promoting the activation of gamma delta (γδ) T cells against cancer cells. Therapies targeting BTN3A or BTN2A1 are under development, but their regulation is …
Figure S2 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S2. BTN2A1 is broadly expressed in normal and tumor cells.
Figure S6 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S6. Anti-BTN2A1 107G3B5 increases Vɣ9Vδ2 T cell effectors functions against hematological cell lines.
Figure S10 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S10. The caspase-3-specific inhibitor zDEVD-FMK inhibits the cleavage of GSDME.
Figure S11 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary figure S11. Anti-BTN2A1 107G3B5 induces a colocalization of BTN3A1 and BTN2A1.
Data from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Vγ9Vδ2 T cells are potent but elusive cytotoxic effectors. Butyrophilin subfamily 2 member A1 (BTN2A1) is a surface protein that has recently been shown to bind the Vγ9 chain of the γδ T-cell receptor, but its precise role in modulating Vγ…
Raw Data Excel File S1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Raw Data Excel File S1
Supplementary Movie 2 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Visualization of Vγ9Vδ2 T cells (E) and SUP-T1 (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 107G3B5 antibody (10ug/ml).
Figure S9 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S9. Anti-BTN2A1 sensitizes Vɣ9Vδ2 T cell cytotoxicity against PC3 cell line.
Supplementary Movie 1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Visualization of Vγ9Vδ2 T cells (E) and SUP-T1 (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 10ug/ml of mIgG1 control antibody.
Figure S12 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure 12. The caspase-3-specific inhibitor zDEVD-FMK inhibits the cleavage of GSDME.
Raw data from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Raw data
Supplementary Movie 3 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Visualization of Vγ9Vδ2 T cells (E) and Ishikawa (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 10ug/ml of mIgG1 control antibody.
Figure S8 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S8. Segmentation of live cells using Refractive Index (RI).
Supplementary Movie 4 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Visualization of Vγ9Vδ2 T cells (E) and Ishikawa (T) coculture using a label-free method within 20 hours. Ratio T/E = 1/2. Cells treated with 107G3B5 antibody (10ug/ml).
Figure S7 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S7. 107G3B5 primes Vγ9Vδ2T cells by mechanisms that are dependent on BTN3A and BTN2Abut independent of the pAg-binding B30.2 intracellular domain.
Figure S3 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S3. BTN2A1 is broadly expressed at the tumor cells surface.
Figure S1 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S1. Gating strategy of ALL blasts and determination of the relative number of BTN2A and BTN3A molecules.
Figure S4 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S4. Anti-BTN2A1 107G3B5 mAb characterization.
Figure S5 from Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Supplementary Figure S5. Cytotoxicity assays of 4 cancer cell lines (PC3, KARPAS, 697 and SUP-T1) and primary ALL blasts (n=4) using Annexin and 7-AAD labelling.
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis Open
Vγ9Vδ2 T cells are potent but elusive cytotoxic effectors. Butyrophilin subfamily 2 member A1 (BTN2A1) is a surface protein that has recently been shown to bind the Vγ9 chain of the γδ T-cell receptor, but its precise role in modulating Vγ…
Targeting BTN2A1 enhances Vγ9Vδ2 T cell effector functions and triggers tumor cells pyroptosis Open
Vγ9Vδ2 T cells are potent but elusive cytotoxic effectors. Means to stimulate their function could lead to powerful new cancer immunotherapies. BTN2A1, a surface protein has recently been shown to bind the Vγ9 chain of the γδ TCR but its p…
View article: Supplementary Data File S1 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Supplementary Data File S1 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Open
TCGA dataset
View article: Supplementary Tables and Figures from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Supplementary Tables and Figures from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Open
This file contains supplementary table 1 and supplementary figures 1-7.
View article: Supplementary Data File S2 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Supplementary Data File S2 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Open
Gating Strategies
View article: Data from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Data from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Open
Dysregulation of lipid metabolism affects the behavior of cancer cells, but how this happens is not completely understood. Neutral sphingomyelinase 2 (nSMase2), encoded by SMPD3, catalyzes the breakdown of sphingomyelin to produce the anti…
View article: Supplementary Data File S2 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Supplementary Data File S2 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Open
Gating Strategies
View article: Data from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Data from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Open
Dysregulation of lipid metabolism affects the behavior of cancer cells, but how this happens is not completely understood. Neutral sphingomyelinase 2 (nSMase2), encoded by SMPD3, catalyzes the breakdown of sphingomyelin to produce the anti…
View article: Supplementary Tables and Figures from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Supplementary Tables and Figures from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Open
This file contains supplementary table 1 and supplementary figures 1-7.
View article: Supplementary Data File S1 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Supplementary Data File S1 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy Open
TCGA dataset